Phong Nguyen, MD
Internal Medicine · Houston, TXNPI 1952345506
Payments from drug & device makers
Across 1,010 payments — averaging $17.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- AstraZeneca$2K
- Novo Nordisk$1K
- GSK$1K
- Lilly USA, LLC$975
- Mannkind Corporation$922
- plus $10K from 49 others
What the payments were for
- Food & beverage$17,88299%
- Education$720%
- Gifts$1191%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LYBALVI$472
- HMG-CoA reductase inhibitor.$274
- FARXIGA$242
- CLINICAL TRIAL PRODUCT$139
- BYDUREON$125
- Vascepa$124
- GENERAL PAIN MANAGEMENT$109
- JARDIANCE$103
How this compares
$18,073 in reported general payments places this provider in the 95th percentile of 7,675 internal medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 162 | $223,612 |
| FarxigaDapagliflozin Propanediol | 120 | $120,922 |
| EliquisApixaban | 80 | $90,648 |
| JardianceEmpagliflozin | 68 | $89,639 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 68 | $73,204 |
| GlyxambiEmpagliflozin/Linagliptin | 58 | $53,864 |
| NucalaMepolizumab | 11 | $47,232 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 39 | $43,572 |
| MounjaroTirzepatide | 40 | $42,578 |
| EntrestoSacubitril/Valsartan | 20 | $38,183 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 34 | $34,849 |
| VascepaIcosapent Ethyl | 50 | $30,625 |
| VraylarCariprazine Hcl | 20 | $29,091 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 39 | $25,151 |
| ArexvyRsvpref3 Antigen/As01e/Pf | 80 | $24,844 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Synjardy Xr, Glyxambi, Tradjenta, Trijardy Xr | $911 | $252,750224 claims |
| Novo NordiskOzempic | $1,376 | $223,612162 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $1,910 | $133,351135 claims |
| GSKNucala, Trelegy Ellipta, Arexvy, Shingrix | $1,215 | $128,797190 claims |
| PfizerEliquis | $338 | $90,64880 claims |
| AbbVieVraylar, Linzess, Restasis | $2,093 | $62,41053 claims |
| Lilly USA, LLCMounjaro, Trulicity | $975 | $60,04858 claims |
| NovartisEntresto | $282 | $38,18320 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $605 | $34,84934 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $530 | $20,30926 claims |
| Johnson & JohnsonXarelto | $328 | $19,33717 claims |
| Kowa Pharmaceuticals America, Inc.Livalo | $623 | $18,97826 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 7,675 internal medicine providers in Texas.
Other internal medicine in Houston
- Jan BurgerHouston$47.3M
- Nitin JainHouston$33.2M
- Aung NaingHouston$30.6M
- Preetesh JainHouston$19.5M
- Paolo StratiHouston$19.2M
- Nicholas ShortHouston$17.6M
- Isabella GlitzaHouston$14.8M
- Murtaza MussajiHouston$13.1M
- Hussein TawbiHouston$12.6M
- Hans LeeHouston$11.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.